Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with histologic proven, corebiopsied, invasive ductal adenocarcinoma of the breast \>2 cm in size and of any N stage (clinical and/or radiological T-stage \> T1, including T4d), scheduled to receive preoperative chemotherapy.~* Age 18-70 years~* ECOG performance-status ≤1~* No prior or current neoplasm except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix~* No distant disease/secondary carcinoma~* Normal cardiac function~* Results of the following assessments at the time of inclusion must be available:~  1. bilateral Mammography (before enrolment)~ 2. histology~ 3. grading~ 4. hormone-receptor-status~ 5. HER2 status negative (is defined as FISH/CISH negative or IHC0 or IHC1+, or IHC2+ and FISH/CISH negative)~* Laboratory requirements (within 1 week before enrolment):~  1. Hematology: Neutrophils ≥ 1.5 x 109/l, Platelets ≥ 100 x 109/l, Hemoglobin\>11 g/dl~ 2. Hepatic function: Total bilirubin \< 1 x ULN, SGOT and SGPT \< 1.5 x ULN, Alkaline phosphatases \< 1.5 x ULN. In case of abnormal values, the liver function tests have to be repeated within 3 days before study treatment.~ 3. Renal function: Creatinine \< 1 x ULN~ 4. Urinalysis: Urine dipstick of proteinuria \< 2+. Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \<1 g of protein / 24 hours.~* Signed and dated Informed Consent before the start of specific protocol procedures~* If of childbearing potential, negative pregnancy test~Exclusion Criteria:~* Cytological only confirmation of diagnosis~* Lobular or other non-ductal types of breast cancer~* Pregnant, or lactating patients; patients of childbearing potential must implement adequate contraceptive measures during study participation~* Pre-existing motor or sensory neurotoxicity of a severity \> grade 2 by NCI-CTC AE~* Preoperative local treatment for breast cancer (i.e. incomplete surgery, radiotherapy)~* Prior or concurrent systemic antitumor therapy~* Evidence of wound healing complications, bone fracture, ulcer or the presence of clinically significant peripheral vascular disease~* Clinically significant cardiac disease e.g. congestive heart failure.~* Other serious illness or medical condition-uncontrolled hypertension or high risk uncontrolled arrythmias -history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent-active uncontrolled infection-unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of corticosteroids~* Known hypersensitivity reaction to the compounds or incorporated substances.~* Evidence of bleeding diathesis or coagulopathy~* The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR, or appropriate monitoring test is within therapeutic limits and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of randomization. Patients not receiving anti coagulant medication must have an INR ≤ 1.5 an aPTT ≤ 1.5 x ULN within 7 days of randomization.~* Ongoing treatment with aspirin (\> 325mg / day) or other medications known to predispose to gastrointestinal ulceration.~* Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrolment.~* Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion~* Treatment with an investigational drug within 30 days prior to study entry.~* Legally incapacitated and/or other circumstances which make it undesirable for the subject to understand the nature, meaning and consequences of the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab/FEC/Docetaxel (Type: EXPERIMENTAL): Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -\> Bevacizumab plus Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).